Unilever is facing a growing investor backlash against its ￡50bn bid for the consumer health unit of GSK, as its share price tumbled to its lowest level in nearly five years.
聯合利華(Unilever)以500億英鎊收購葛蘭素史克(GSK)消費者健康部門的交易，正面臨越來越多的投資者反彈，該公司股價跌至近5年來的最低水平。
您已閱讀4%（249字），剩余96%（5514字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。